Plasminogen activator inhibitor 1 (PAI-1): In vitro activities and clinical relevance

British Journal of Haematology

Volumn 125, Issue 1, 2004, Pages 12-23

  Horrevoets, Anton J G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulation; Fibrinolysis; PAI 1; Plasminogen activator; Thrombin

Indexed keywords

ACTIVATED PROTEIN C; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BLOOD CLOTTING; ENZYME INHIBITION; FEEDBACK SYSTEM; GENETIC POLYMORPHISM; HEMOSTASIS; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; THROMBOGENESIS;

ANIMALS; BLOOD COAGULATION; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEPSIS; THROMBOSIS;

EID: 1842610168     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04844.x     Document Type: Review

References (119)

1. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group (2003) No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation, 107, 1117-1122.
2. Bajou, K., Masson, V., Gerard, R.D., Schmitt, P.M., Albert, V., Praus, M., Lund, L.R., Frandsen, T.L., Brunner, N., Dano, K., Fusenig, N.E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J.M. & Noel, A. (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. Journal of Cell Biology, 152, 777-784.
3. Berkenpas, M.B., Lawrence, D.A. & Ginsburg, D. (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO Journal, 14, 2969-2977.
4. Biemond, B.J., Levi, M., Coronel, R., Janse, M.J., ten Cate, J.W. & Pannekoek, H. (1995a) Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation, 91, 1175-1181.
5. Biemond, B.J., Levi, M., Ten Cate, H., Van der Poll, T., Buller, H.R., Hack, C.E. & Ten Cate, J.W. (1995b) Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clinical Science (London), 88, 587-594.
6. Boekholdt, S.M., Bijsterveld, N.R., Moons, A.H., Levi, M., Buller, H.R. & Peters, R.J. (2001) Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation, 104, 3063-3068.
7. van der Bom, J.G., Bots, M.L., Haverkate, F., Kluft, C. & Grobbee, D.E. (2003) The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood, 101, 1841-1844.
8. Carmeliet, P., Stassen, J.M., Schoonjans, L., Ream, B., van den Oord, J.J., De Mol, M., Mulligan, R.C. & Collen, D. (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. Journal of Clinical Investigation, 92, 2756-2760.
9. Carmeliet, P., Moons, L., Lijnen, R., Janssens, S., Lupu, F., Collen, D. & Gerard, R.D. (1997) Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96, 3180-3191.
10. Chazaud, B., Ricoux, R., Christov, C., Plonquet, A., Gherardi, R.K. & Barlovatz-Meimon, G. (2002) Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. American Journal of Pathology, 160, 237-246.
11. Cui, J., Eitzman, D.T., Westrick, R.J., Christie, P.D., Xu, Z.J., Yang, A.Y., Purkayastha, A.A., Yang, T.L., Metz, A.L., Gallagher, K.P., Tyson, J.A., Rosenberg, R.D. & Ginsburg, D. (2000) Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood, 96, 4222-4226.
12. Czekay, R.P., Aertgeerts, K., Curriden, S.A. & Loskutoff, D.J. (2003) Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. Journal of Cell Biology, 160, 781-791.
13. Dekker, R.J., Eichinger, A., Stoop, A.A., Bode, W., Pannekoek, H. & Horrevoets, A.J. (1999) The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop. Journal of Molecular Biology, 293, 613-627.
14. Dekker, R.J., Pannekoek, H. & Horrevoets, A.J. (2003) A steady-state competition model describes the modulating effects of thrombomodulin on thrombin inhibition by plasminogen activator inhibitor-1 in the absence and presence of vitronectin. European Journal of Biochemistry, 270, 1942-1951.
15. Deng, G., Curriden, S.A., Hu, G., Czekay, R.P. & Loskutoff, D.J. (2001) Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. Journal of Cell Physiology, 189, 23-33.
16. Duffy, M.J. (2002) Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clinical Chemistry, 48, 1194-1197.
17. Edelberg, J.M., Christie, P.D. & Rosenberg, R.D. (2001) Regulation of vascular bed-specific prothrombotic potential. Circulation Research, 89, 117-124.
18. Ehrlich, H.J., Gebbink, R.K., Keijer, J., Linders, M., Preissner, K.T. & Pannekoek, H. (1990) Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. Journal of Biological Chemdistry, 265, 13029-13035.
19. Ehrlich, H.J., Gebbink, R.K., Preissner, K.T., Keijer, J., Esmon, N.L., Mertens, K. & Pannekoek, H. (1991) Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. Journal of Cell Biology, 115, 1773-1781.
20. Eitzman, D.T., McCoy, R.D., Zheng, X., Fay, W.P., Shen, T., Ginsburg, D. & Simon, R.H. (1996) Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. Journal of Clinical Investigation, 97, 232-237.
21. Eitzman, D.T., Westrick, R.J., Nabel, E.G. & Ginsburg, D. (2000a) Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood, 95, 577-580.
22. Eitzman, D.T., Westrick, R.J., Xu, Z., Tyson, J. & Ginsburg, D. (2000b) Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood, 96, 4212-4215.
23. Esmon, C.T. (2000) Regulation of blood coagulation. Biochimica et Biophysica Acta, 1477, 349-360.
24. Farrehi, P.M., Ozaki, C.K., Carmeliet, P. & Fay, W.P. (1998) Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation, 97, 1002-1008.
25. Fay, W.P. & Owen, W.G. (1989) Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C. Biochemistry, 28, 5773-5778.
26. Fay, W.P., Shapiro, A.D., Shih, J.L., Schleef, R.R. & Ginsburg, D. (1992) Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. New England Journal of Medicine, 327, 1729-1733.
27. Fay, W.P., Eitzman, D.T., Shapiro, A.D., Madison, E.L. & Ginsburg, D. (1994) Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood, 83, 351-356.
28. Fay, W.P., Parker, A.C., Condrey, L.R. & Shapiro, A.D. (1997) Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood, 90, 204-208.
29. Fay, W.P., Parker, A.C., Ansari, M.N., Zheng, X. & Ginsburg, D. (1999) Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood, 93, 1825-1830.
30. Festa, A., D'Agostino, Jr, R., Rich, S.S., Jenny, N.S., Tracy, R.P. & Haffner, S.M. (2003) Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study. Circulation, 107, 2422-2427.
31. Folsom, A.R. (2001) Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thrombosis and Haemostasis, 86, 366-373.
32. de Fouw, N.J., de Jong, Y.F., Haverkate, F. & Bertina, R.M. (1988) Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor - no evidence for a cofactor role of protein S. Thrombosis and Haemostasis, 60, 328-333.
33. Francis, C.W. (2002) Plasminogen activator inhibitor-1 levels and polymorphisms: association with venous thromboembolism. Archives of Pathology and Laboratory Medicine, 126, 1401-1404.
34. Friederich, P.W., Levi, M., Biemond, B.J., Charlton, P., Templeton, D., van Zonneveld, A.J., Bevan, P., Pannekoek, H. & ten Cate, J.W. (1997) Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation, 96, 916-921.
35. Gebbink, R.K., Reynolds, C.H., Tollefsen, D.M., Mertens, K. & Pannekoek, H. (1993) Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. Biochemistry, 32, 1675-1680.
36. Ginsburg, D., Zeheb, R., Yang, A.Y., Rafferty, U.M., Andreasen, P.A., Nielsen, L., Dano, K., Lebo, R.V. & Gelehrter, T.D. (1986) cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. Journal of Clinical Investigation, 78, 1673-1680.
37. Henry, M., Chomiki, N., Scarabin, P.Y., Alessi, M.C., Peiretti, F., Arveiler, D., Ferrieres, J., Evans, A., Amouyel, P., Poirier, O., Cambien, F. & Juhan-Vague, I. (1997) Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arteriosclerosis, Thrombosis and Vascular Biology, 17, 851-858.
38. Horn, I.R., van den Berg, B.M., Moestrup, S.K., Pannekoek, H. & van Zonneveld, A.J. (1998) Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator. Thrombosis and Haemostasis, 80, 822-828.
39. Horrevoets, A.J., Tans, G., Smilde, A.E., van Zonneveld, A.J. & Pannekoek, H. (1993) Thrombin-variable region 1 (VR1). Evidence for the dominant contribution of VR1 of serine proteases to their interaction with plasminogen activator inhibitor 1. Journal of Biological Chemistry, 268, 779-782.
40. Horrevoets, A.J., Pannekoek, H. & Nesheim, M.E. (1997) A steady-state template model that describes the kinetics of fibrin-stimulated [Glu1]-and [Lys78]plasminogen activation by native tissue-type plasminogen activator and variants that lack either the finger or kringle-2 domain. Journal of Biological Chemistry, 272, 2183-2191.
41. Hoylaerts, M., Rijken, D.C., Lijnen, H.R. & Collen, D. (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. Journal of Biological Chemistry, 257, 2912-2919.
42. Idell, S., Peters, J., James, K.K., Fair, D.S. & Coalson, J.J. (1989) Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. Journal of Clinical Investigation, 84, 181-193.
43. Ihara, H., Urano, T., Takada, A. & Loskutoff, D.J. (2001) Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones. FASEB Journal, 15, 1233-1235.
44. Isermann, B., Hendrickson, S.B., Zogg, M., Wing, M., Cummiskey, M., Kisanuki, Y.Y., Yanagisawa, M. & Weiler, H. (2001) Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. Journal of Clinical Investigation, 108, 537-546.
45. Iwai, N., Shimoike, H., Nakamura, Y., Tamaki, S. & Kinoshita, M. (1998) The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis, 136, 109-114.
46. Juhan-Vague, I., Alessi, M.C., Mavri, A. & Morange, P.E. (2003) Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. Journal of Thrombosis and Haemostasis, 1, 1575-1579.
47. Keijer, J., Linders, M., Wegman, J.J., Ehrlich, H.J., Mertens, K. & Pannekoek, H. (1991a) On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood, 78, 1254-1261.
48. Keijer, J., Ehrlich, H.J., Linders, M., Preissner, K.T. & Pannekoek, H. (1991b) Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator. Journal of Biological Chemistry, 266, 10700-10707.
49. Konstantinides, S., Schäfer, K., Thinnes, T. & Loskutoff, D.J. (2001) Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation, 103, 576-583.
50. Konstantinides, S., Schäfer, K. & Loskutoff, D.J. (2002) Do PAI-1 and vitronectin promote or inhibit neoinn'ma formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain. Arteriosclerosis, Thrombosis and Vascular Biology, 22, 1943-1945.
51. Kruithof, E.K., Tran-Thang, C. & Bachmann, F. (1986) Studies on the release of a plasminogen activator inhibitor by human platelets. Thrombosis and Haemostasis, 55, 201-205.
52. Kunz, G., Ohlin, A.K., Adami, A., Zoller, B., Svensson, P. & Lane, D.A. (2002) Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function. Blood, 99, 3646-3653.
53. Lane, D.A. & Grant, P.J. (2000) Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood, 95, 1517-1532.
54. Lawrence, D.A., Berkenpas, M.B., Palaniappan, S. & Ginsburg, D. (1994) Localization of vitronectin binding domain in plasminogen activator inhibitor-1. Journal of Biological Chemistry, 269, 15223-15228.
55. Lawrence, D.A., Palaniappan, S., Stefansson, S., Olson, S.T., Francis-Chmura, A.M., Shore, J.D. & Ginsburg, D. (1997) Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. Journal of Biological Chemistry, 272, 7676-7680.
56. Levi, M., Biemond, B.J., van Zonneveld, A.J., ten Cate, J.W. & Pannekoek, H. (1992) Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation, 85, 305-312.
57. Levi, M., Schultz, M.J., Rijneveld, A.W. & van der Poll, T. (2003) Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Critical Care Medicine, 31, S238-S242.
58. Loskutoff, D.J., Linders, M., Keijer, J., Veerman, H., van Heerikhuizen, H. & Pannekoek, H. (1987) Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. Biochemistry, 26, 3763-3768.
59. Loskutoff, D.J., Fujisawa, K. & Samad, F. (2000) The fat mouse. A powerful genetic model to study hemostatic gene expression in obesity/NIDDM. Annals of the New York Acadamy of Sciences, 902, 272-282.
60. Luttun, A., Lupu, F., Storkebaum, E., Hoylaerts, M. F., Moons, L., Crawley, J., Bono, F., Poole, A.R., Tipping, P., Herbert, J.M., Collen, D. & Carmeliet, P. (2002) Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis and Vascular Biology, 22, 499-505.
61. McMahon, G.A., Petitclerc, E., Stefansson, S., Smith, E., Wong, M.K., Westrick, R.J., Ginsburg, D., Brooks, P.C. & Lawrence, D.A. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. Journal of Biological Chemistry, 276, 33964-33968.
62. Madison, E.L., Goldsmith, E.J., Gerard, R.D., Gething, M.J. & Sambrook, J.F. (1989) Serpin-resistant mutants of human tissue-type plasminogen activator. Nature, 339, 721-724.
63. van Meijer, M. & Pannekoek, H. (1995) Structure of PAI-1 and its function in fibrinolysis: an update. Fibrinolysis, 9, 263-276.
64. van Meijer, M., Roelofs, Y., Neels, J., Horrevoets, A.J., van Zonneveld, A.J. & Pannekoek, H. (1996) Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator. Journal of Biological Chemistry, 271, 7423-7428.
65. van Meijer, M., Stoop, A., Smilde, A., Preissner, K.T., van Zonneveld, A.J. & Pannekoek, H. (1997a) The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator. Thrombosis and Haemostasis, 77, 516-521.
66. van Meijer, M., Smilde, A., Tans, G., Nesheim, M.E., Pannekoek, H. & Horrevoets, A.J. (1997b) The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood, 90, 1874-1882.
67. Mesters, R.M., Florke, N., Ostermann, H. & Kienast, J. (1996) Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thrombosis and Haemostasis, 75, 902-907.
68. Morange, P.E., Henry, M., Tregouet, D., Granel, X., Aillaud, M.F., Alessi, M.C. & Juhan-Vague, I. (2000) The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arteriosclerosis Thrombosis and Vascular Biology, 20, 1387-1391.
69. Mottonen, J., Strand, A., Symersky, J., Sweet, R.M., Danley, D.E., Geoghegan, K.F., Gerard, R.D. & Goldsmith, E.J. (1992) Structural basis of latency in plasminogen-activator inhibitor-1. Nature, 355, 270-273.
70. van Mourik, J.A., Lawrence, D.A. & Loskutoff, D.J. (1984) Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. Journal of Biological Chemistry, 259, 14914-14921.
71. Naski, M.C., Lawrence, D.A., Mosher, D.F., Podor, T.J. & Ginsburg, D. (1993) Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. Journal of Biological Chemistry, 268, 12367-71232.
72. Nesheim, M.E. (1983) A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin. Journal of Biological Chemistry, 258, 1 4708-1 4717.
73. Nordt, T.K., Eschenfelder, E., Peter, K., Sobel, B.E. & Bode, C. (2003) Independence of growth factor induced plasminogen activator inhibitor type-1 (PAI-1) expression from the 4G/5G polymorphism of the PAI-1 gene. Thrombosis and Haemostasis, 90, 36-42.
74. Ny, T., Sawdey, M., Lawrence, D., Millan, J.L. & Loskutoff, D.J. (1986) Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 83, 6776-6780.
75. Okumura, Y., Kamikubo, Y., Curriden, S.A., Wang, J., Kiwada, T., Futaki, S., Kitagawa, K. & Loskutoff, D.J. (2002) Kinetic analysis of the interaction between vitronectin and the urokinase receptor. Journal of Biological Chemistry, 277, 9395-9404.
76. Pannekoek, H., Veerman, H., Lambers, H., Diergaarde, P., Verweij, C.L., van Zonneveld, A.J. & van Mourik, J.A. (1986) Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO Journal, 5, 2539-2544.
77. Peng, L., Bhatia, N., Parker, A.C., Zhu, Y. & Fay, W.P. (2002) Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arteriosclerosis, Thrombosis and Vascular Biology, 22, 934-939.
78. Podor, T.J., Peterson, C.B., Lawrence, D.A., Stefansson, S., Shaughnessy, S.G., Foulon, D.M., Butcher, M. & Weitz, J.L. (2000) Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. Journal of Biological Chemistry, 275, 1 9788-1 9794.
79. van der Poll, T., Levi, M., Buller, H.R., van Deventer, S.J., de Boer, J.P., Hack, C.E. & ten Cate, J.W. (1991) Fibrinolytic response to tumor necrosis factor in healthy subjects. Journal of Experimental Medicine, 174, 729-732.
80. Pralong, G., Calandra, T., Glauser, M.P., Schellekens, J., Verhoef, J., Bachmann, F. & Kruithof, E.K. (1989) Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thrombosis and Haemostasis, 61, 459-462.
81. Preissner, K.T., Grulich-Henn, J., Ehrlich, H.J., Declerck, P., Justus, C., Collen, D., Pannekoek, H. & Muller-Berghaus, G. (1990) Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. Journal of Biological Chemistry, 265, 1 8490-1 8498.
82. Rezaie, A.R. (1999) Role of exosites 1 and 2 in thrombin reaction with plasminogen activator inhibitor-1 in the absence and presence of cofactors. Biochemistry, 38, 1 4592-1 4599.
83. Rezaie, A.R. (2001) Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. Journal of Biological Chemistry, 276, 1 5567-1 5570.
84. Rezaie, A.R., Cooper, S.T., Church, F.C. & Esmon, C.T. (1995) Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. Journal of Biological Chemistry, 270, 2 5336-2 5339.
85. Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M. & Ruf, W. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 296, 1880-1882.
86. Rijneveld, A.W., Florquin, S., Bresser, P., Levi, M., De Waard, V., Lijnen, R., Van Der Zee, J.S., Speelman, P., Carmeliet, P. & Van Der Poll, T. (2003) Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood, 102, 934-939.
87. Robbie, L.A., Young, S.P., Bennett, B. & Booth, N.A. (1997) Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and RAI-1 content and distribution. Thrombosis and Haemostasis, 77, 510-515.
88. Sakata, Y., Curriden, S., Lawrence, D., Griffin, J.H. & Loskutoff, D.J. (1985) Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proceedings of the National Academy of Sciences of the United States of America, 82, 1121-1125.
89. Samad, F., Uysal, K.T., Wiesbrock, S.M., Pandey, M., Hotamisligil, G.S. & Loskutoff, D.J. (1999) Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proceedings of the National Academy of Sciences of the United States of America, 96, 6902-6907.
90. Samad, F., Pandey, M., Bell, P.A. & Loskutoff, D.J. (2000) Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Molecular Medicine, 6, 680-692.
91. Schäfer, K., Fujisawa, K., Konstantinides, S. & Loskutoff, D.J. (2001) Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB Journal, 15, 1840-1842.
92. Schäfer, K., Muller, K., Hecke, A., Mounier, E., Goebel, J., Loskutoff, D.J. & Konstantinides, S. (2003) Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arteriosclerosis, Thrombosis and Vascular Biology, 23, 2097-2103.
93. Schneiderman, J., Sawdey, M.S., Keeton, M.R., Bordin, G. M., Bernstein, E.F., Dilley, R.B. & Loskutoff, D.J. (1992) Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proceedings of the National Academy of Sciences of the United States of America, 89, 6998-7002.
94. Sherman, P.M., Lawrence, D.A., Verhamme, I.M., Paielli, D., Shore, J.D. & Ginsburg, D. (1995) Identification of tissue-type plasminogenactivator- specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. Journal of Biological Chemistry, 270, 9301-9306.
95. Sjoland, H., Eitzman, D.T., Gordon, D., Westrick, R., Nabel, E.G. & Ginsburg, D. (2000) Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arteriosclerosis, Thrombosis and Vascular Biology, 20, 846-852.
96. Smith, E.B., Crosbie, L. & Carey, S. (1996) Prothrombin-related antigens in human aortic intima. Seminars in Thrombosis and Hemostasis, 22, 347-350.
97. Stefansson, S. & Lawrence, D.A. (1996) The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature, 383, 441-443.
98. Stefansson, S., Lawrence, D.A. & Argraves, W.S. (1996) Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. Journal of Biological Chemistry, 271, 8215-8220.
99. Stefansson, S., Muhammad, S., Cheng, X.F., Battey, F.D., Strickland, D.K. & Lawrence, D.A. (1998) Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. Journal of Biological Chemistry, 273, 6358-6366.
100. Stefansson, S., Petitclerc, E., Wong, M.K., McMahon, G.A., Brooks, P.C. & Lawrence, D.A. (2001) Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. Journal of Biological Chemistry, 276, 8135-8141.
101. Stoop, A.A., Lupu, F. & Pannekoek, H. (2000) Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: a potential regulatory mechanism of thrombin activity by PAI-1/ vitronectin complexes. Arteriosclerosis, Thrombosis and Vascular Biology, 20, 1143-1149.
102. Stoop, A.A., Eldering, E., Dafforn, T.R., Read, R.J. & Pannekoek, H. (2001) Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. Journal of Molecular Biology, 305, 773-783.
103. Stringer, H.A., van Swieten, P., Horrevoets, A.J., Smilde, A. & Pannekoek, H. (1994a) The role of the finger domain of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in initiation and progression of thrombolysis. Thrombosis and Haemostasis, 72, 900-905.
104. Stringer, H.A., van Swieten, P., Heijnen, H.F., Sixma, J.J. & Pannekoek, H. (1994b) Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arteriosclerosis and Thrombosis, 14, 1452-1458.
105. Tachias, K. & Madison, E.L. (1997) Variants of tissue-type plasminogen activator that display extraordinary resistance to inhibition by the serpin plasminogen activator inhibitor type 1. Journal of Biological Chemistry, 272, 14580-14585.
106. Takeshita, K., Yamamoto, K., Ito, M., Kondo, T., Matsushita, T., Hirai, M., Kojima, T., Nishimura, M., Nabeshima, Y., Loskutoff, D.J., Saito, H. & Murohara, T. (2002) Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "Klotho" mouse. Seminars in Thrombosis and Hemostasis, 28, 545-554.
107. Tanaka, S., Koyama, H., Ichii, T., Shioi, A., Hosoi, M., Raines, E.W. & Nishizawa, Y. (2002) Fibrillar collagen regulation of plasminogen activator inhibitor-1 is involved in altered smooth muscle cell migration. Arteriosclerosis, Thrombosis and Vascular Biology, 22, 1573-1578.
108. Vaughan, D.E. (2002) PAI-1 and cellular migration: dabbling in paradox. Arteriosclerosis, Thrombosis and Vascular Biology, 22, 1522-1523.
109. Visanji, J.M., Seargent, J., Tahri, D., Croft, S.A., Makris, M., Preston, F.E., Peake, I.R. & Daly, M.E. (2000) Influence of the -675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. British Journal of Haematology, 110, 135-138.
110. Waard, V., Arkenbout, E.K., Carmeliet, P., Lindner, V. & Pannekoek, H. (2002) Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arteriosclerosis, Thrombosis and Vascular Biology, 22, 1978-1983.
111. Wagner, O.F., de Vries, C., Hohmann, C., Veerman, H. & Pannekoek, H. (1989) Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. Journal of Clinical Investigation, 84, 647-655.
112. Weiler, H., Lindner, V., Kerlin, B., Isermann, B.H., Hendrickson, S.B., Cooley, B.C., Meh, D.A., Mosesson, M.W., Shworak, N.W., Post, M.J., Conway, E.M., Ulfman, L.H., von Andrian, U.H. & Weitz, J.I. (2001) Characterization of a mouse model for thrombomodulin deficiency. Arteriosclerosis Thrombosis and Vascular Biology, 21, 1531-1537.
113. Wu, K.K. & Matijevic-Aleksic, N. (2000) Thrombomodulin: a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis. Annals of Medicine, 32, (Suppl. 1), 73-77.
114. Yamamoto, K., Shimokawa, T., Yi, H., Isobe, K., Kojima, T., Loskutoff, D.J. & Saito, H. (2002a) Aging accelerates endotoxin-induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. American Journal of Pathology, 161, 1805-1814.
115. Yamamoto, K., Takeshita, K., Shimokawa, T., Yi, H., Isobe, K., Loskutoff, D.J. & Saito, H. (2002b) Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proceedings of the National Academy of Sciences of the United States of America, 99, 890-895.
116. Yang, L., Manithody, C., Walston, T.D., Cooper, S.T. & Rezaie, A.R. (2003) Thrombomodulin enhances the reactivity of thrombin with protein C inhibitor by providing both a binding site for the serpin and allosterically modulating the activity of thrombin. Journal of Biological Chemistry, 278, 37465-37470.
117. Zhou, A., Huntington, J.A., Pannu, N.S., Carrell, R.W. & Read, R.J. (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nature Structural Biology, 10, 541-544.
118. Zhu, Y., Carmeliet, P. & Fay, W.P. (1999) Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation, 99, 3050-3055.
119. Zhu, Y., Farrehi, P.M. & Fay, W.P. (2001) Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation, 103, 3105-3110.